To show non-inferiority of the 67-or 87 mm thick, sirolimus-eluting Orsiro drug eluting stent (DES) to the 122 mm thick, biolimus-eluting Nobori DES regarding size of vessel lumen outside the stent at 13-month follow-up. 
Introduction
First generation coronary drug eluting stents (DES) with permanent polymers are associated with increased risk of late-and very late stent thrombosis (ST) when compared with bare metal stents (BMS). the vessel wall. [3] [4] [5] Newer generation DES designed with biocompatible polymers improved the DES safety profile, 6 and latest generation DES with thinner stent platforms and biodegradable polymers were aimed to improve early healing and reduce the risk of adverse longterm reactions. 7 Differences in stent platforms, biocompatibility, and degradation pace of polymers may influence healing patterns. 8 The purpose of this study was to compare 13-month stent performance and vessel wall healing response, evaluated by optical coherence tomography (OCT), after implantation of the 67-87 mm thick, sirolimus-eluting Orsiro DES (Biotronik, Germany), and a 122 mm thick biolimus-eluting Nobori DES (Terumo, Jp) in patients with stable angina pectoris (SAP) or acute coronary syndrome (ACS).
Methods

Study design
The SORT-OUT VII OCT study was a substudy to the clinical SORT-OUT VII trial (NCT01879358), a prospective, randomized, multi-centre, all-comer trial, enrolling 2525 patients. The substudy was conducted at Odense University Hospital and Aarhus University Hospital, Denmark. The OCT substudy was notified after first enrollment in the main SORT-OUT VII study. Randomization was stratified by gender and diabetes, and participation in the OCT substudy. Patients eligible for the substudy were included with a planned target of 120 patients. Patients were randomized 1:1 to receive either sirolimus-eluting Orsiro DES (Biotronik TM , Berlin, Germany) or biolimuseluting Nobori DES (Terumo Corporation   TM , Tokyo, Japan). Randomization was stratified by sex and diabetes, and participation in the OCT substudy. OCT was performed immediately after percutaneous coronary intervention (PCI) and at 13-month follow-up. The study included patients aged > _ 18 years with stable-or unstable coronary artery disease, ST-segment elevation myocardial infarction (STEMI) or non-ST segment elevation myocardial infarction (NSTEMI), and at least one coronary lesion with more than 50% diameter stenosis. Exclusion criteria for this substudy were aorto-ostial lesions, s-creatinine > 120mmol/L, severely tortuous target coronary artery, life expectancy less than 1 year, allergy to aspirin, clopidogrel, ticagrelor, prasugrel, sirolimus, or biolimus. The main SORT-OUT VII trial and the SORT-OUT VII OCT substudy were approved by The Central Denmark Region Committees on Health Research Ethics. All patients provided written informed consent for participation in the trial (NCT01879358).
Study stents
The CE-certified Orsiro DES is designed with a permanent thin 'ProBIO' coating aimed at reducing ion-release, and a poly-L-lactic acid biodegradable polymer eluting sirolimus during the first 12-14 weeks. The polymer is almost completely degraded within 1-2 years. The stent features two different platform designs; a small size (diameters 2.25 to 3.0 mm, strut thickness 60 þ 7 mm polymer) and a larger size (diameters 3.5 to 4.0 mm, strut thickness 80 þ 7 mm polymer). 9 The CE-certified Nobori DES is based on a stainless steel platform with a thin permanent parylene coating, and a biodegradable polymer coating of the abluminal side of struts. The polymer elutes biolimus A9 (Biosensors International, Singapore) for the first approximately 30 days during the polymer degradation lasting 6-9 months. Strut thickness is 112 þ 10 lm polymer. 10 
Study procedure
Medical treatment and PCI was performed according to standard procedures as previously described. 11 Use of pre-dilatation of the lesion, direct stenting or post-dilatation of the stent was decided by the PCI-operator, OCT could be used for evaluating the procedure at the discretion of the operator, and the baseline OCT-recording was performed as the final intervention before removing the guide wire.
OCT acquisition
OCT imaging was performed using the St. Jude Medical OCT-system (Illumien  TM or Illumien OPTIS   TM ) and a C7 Dragonfly TM catheter (St.
Jude Medical, Minnesota, MN, USA) after intracoronary administration of nitroglycerine. OCT images were recorded at either 100 frames per second (fps) with a catheter pullback speed of 20 mm/s, or 180 fps with pullback speed 18 or 36 mm/s during flushing with contrast.
Clinical follow-up and endpoints
Clinical endpoints included all-cause mortality, cardiac death, myocardial infarction (MI), ST, and target lesion revascularization (TLR). The endpoints were obtained from health registries covering from discharge until 13-month angiography. Additional clinical endpoint definitions were described in the SORT-OUT VII main study.
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OCT analysis
OCT acquired post-PCI and at 13-month follow-up were matched at frame-level and analysed by blinded observers using off-line semi-automated analysis software (QCU-CMS Research, Leiden, The Netherlands). The entire stent segment, including the margins 5 mm proximal and distal to the stent, were evaluated in all consecutive frames for recording quality, plaque type and extend, and thrombus. Thrombus was defined as an irregular mass appearing in the lumen with or without attachment to the vessel wall ( Figure 1C ). Quantitative OCT analysis was performed at 0.5 or 0.6 mm intervals after calibration of the OCT recordings. Lumen and stent contours, and areas were measured. At follow-up, tissue coverage was evaluated visually for each strut and neointimal thickness (NIT) was measured as the shortest distance from the centre of the strut blooming signal to the lumen border ( Figure 1D ). Struts were considered malapposed when the smallest distance from the centre of the leading strut blooming signal to the lumen contour exceeded the sum of the strut thickness þ polymer þ 20 mm ( Figure 1F ). Clusters of malapposed struts were defined as 10 counts of malapposed struts within five or less consecutive frames. At follow-up, clusters were classified into persistent, abolished or acquired.
Primary and secondary endpoints (OCT)
The primary endpoint of mean extra stent lumen (ESL) was evaluated by OCT at 13-month follow-up. ESL was defined as lumen area outside the stent contour ( Figure 1A) . Secondary endpoints included change in mean ESL from baseline to follow-up. Maximum ESL was measured and defined as the largest total area outside stent in one frame ( Figure 1B ). Maximum ESL at frame level was defined as the maximal area outside stent limited by two apposed struts ( Figure 1B, B1 ). Additional secondary endpoints were malapposition at baseline and at 13-month follow-up, persistent-, abolished-, or acquired malapposed clusters, stent area late loss (late recoil), minimal lumen area (MLA), neointimal thickness (NIT), thrombus on stent struts at baseline, in-stent thrombus at follow-up and mean neointimal area calculated and measured as the area delineated abluminal by the stent contour and luminal by the lumen contour.
Sample size
Experience by treatment with the sirolimus eluting Cypher stent has demonstrated that evaginations and aneurysm formation are reflected in an increased maximum ESL of 0.60 ± 0.83 mm 2 at a mean 1-year follow-up. 12 The mean ESL area was estimated to be 0.30 mm 2 
Statistics
Continuous variables are presented as mean ± standard deviation if following a Gaussian distribution or alternatively as median and interquartile range. Non-parametric data are presented as absolute numbers and percentages. Differences in characteristics between the two DES were compared using Student's t-test or Mann-Whitney test as appropriate. v 2 test was used for comparing categorical variables, alternative Fisher's exact test in case of cell values less than 5. Due to a non-normal distribution of the primary endpoint data of mean ESL at 13-month, several transformations were made to find the most appropriate transformation (log (ESL þ 0.001)). Median values and confidence intervals (CI) of the transformed analysis were back transformed and compared with the preplanned analysis to evaluate if non-inferiority of Orsiro DES to Nobori DES was met. Statistical significance was accepted for P-values < 0.05. All statistical analyses were performed using STATA version 13 (STATA Inc., College Station, TX).
Results
We included 124 randomized patients in the OCT substudy between June 2013 and February 2014. Sixty patients were treated with the Orsiro DES, while 64 patients were treated with the Nobori DES. Clinical follow-up at 13-month was available in all patients. Baseline characteristics were well balanced between the two groups, except for treatment indication, which varied between stable-and unstable angina pectoris between the two groups ( Table 1 ). All patients received the allocated study stent. Almost 15% of the patients in both groups had diabetes. The most frequently treated vessel in both groups was LAD (Orsiro: 55%, Nobori: 50%, P = 0.52) ( Table 2) .
Clinical results
At 13-month clinical follow-up, NSTEMI occurred in one of 60 patients in the Orsiro group and one of 64 patients in the Nobori group. No patients had stent thrombosis. One patient treated with a Nobori DES suffered non-cardiac death. (Nobori DES), (P = 0.13)). A total of 6 patients (13%) in the Orsiro treated group and 9 patients (21%) treated with a Nobori DES showed coverage levels below 90% after 13-month ( Figure 4A) , P = 0.0001) ( Figure 4B and C) .
Malapposition
At baseline, malapposed struts were found in 2.9% [0.4;10.0] % and 2.1% [0.7;6.8] % of analysed struts in the Orsiro, and the Nobori DES respectively (P = 0.66). At 13-month follow-up, malapposition was 0.0% [0.0;1.1] % (Orsiro DES) and 0.0% [0.0;0.5] % (Nobori DES), (P = 0.37). We found no difference in number of patients with clustered baseline malapposition; 24 patients with a total of 37 clusters in the Orsiro group compared with 19 patients with a total of 30 clusters in the Nobori group (P = 0.39). Clusters of acquired malapposition at follow-up were found in four patients (9%) in the Orsiro group and two patients (5%) in the Nobori group (P = 0.68). Number of patients having clusters of persistent or resolved of malapposed clusters did not differ between the stents (Orsiro: 6 patients (13%), Nobori: 2 patients (5%), P = 0.27 and Orsiro: 20 patients (44%), Nobori: 18 patients (42%), P = 0.81, respectively (Supplementary data online, Table S1 ). ). Additional secondary endpoint results are shown in Table 3 .
Discussion
The main findings of the SORT-OUT VII OCT study were as follows: (i) The pre-specified statistic test for non-inferiority showed that Orsiro did not exceed the limit for non-inferiority, but the distribution of data was non-normal and most optimal transformation applied posthoc showed that it could not be excluded that Orsiro exceeded the limit for non-inferiority, (ii) testing for superiority, Orsiro showed significantly larger mean ESL at 13-month follow-up than Nobori, (iii) Orsiro DES had significantly larger increase in mean ESL from baseline to follow-up than Nobori DES, and the difference persisted in sensitivity analysis excluding the worst, most aneurysmatic cases in the Orsiro group, (iv) Nobori DES had a significantly larger mean neointima area and larger mean lumen area late loss, (v) strut coverage was complete or almost complete in the vast majority of patients but in both groups some stents still had coverage below 90% at 13-month follow-up, and (vi) all other healing parameters did not differ between the two stents.
The finding in the main SORT-OUT VII study of similar 1-year clinical outcome after Orsiro and Nobori DES treatment except that more patients had ST in the Nobori group 11 could indicate that the increased ESL in Orsiro either is not causing clinical events or the patients have been protected from ST by DAPT the first 12 months. An extended follow-up time is required to determine the associated risk when DAPT is discontinued. Still, the overall slightly more heterogeneous healing pattern in Nobori treated vessels might increase the risk of clinical events more than increased ESL as reflected in the difference in 1-year ST.
Aneurysms and extra stent lumen
Angiographic detected coronary aneurysms after DES implantation are infrequent findings with an incidence of 0.3 to 6.0%. 13, 14 Aneurysms are defined as localized angiographic dilatation of a segment of the coronary artery more than 50% larger than the adjacent reference vessel. 15 Angiographic dilation <50% of the reference vessel at the site of a stent with contrast staining outside is known as peri-stent contrast staining (PSS). 15 PSS corresponds to a segment of OCT-detected ESL or evagination. 16 Both angiographic aneurysms, PSS and larger OCT-detected ESL have been associated with increased risk of ST. 13, [15] [16] [17] A previous study evaluating the occurrence of OCT-detected ESL in different DESs reported that ESL was related to treatment by the first generation sirolimus-eluting stent (Cypher Select) and was almost completely absent in newer generation DES. 17 The present study challenges these findings as major aneurysms were formed in the Orsiro group during follow-up ( Figure 5 ) and a number of minor aneurysms or clearly explicable evaginations were found in both groups. It cannot be excluded that formation of larger aneurysms could be due to injury to the vessel wall and thus not related to any specific stent type. Nevertheless, the increased ESL from baseline to follow-up in Orsiro treated patients was significant despite excluding the cases with large aneurysms from the analysis. The polymer degradation time for the Orsiro DES is 1-2 years and 6-9 months for the Nobori DES. The increase in ESL at 13 
Coverage and degree of neointima
Incomplete neointimal coverage is a predictor of late ST. A ratio of uncovered to all struts exceeding 30% in 2-3 mm long in-stent sections was found in a histopathological study to be associated with ST. 4 Both stent groups in this study showed on average a high degree of coverage after 13-month but with an uneven distribution, and an unsettling fraction of patients in both arms had more than 10% uncovered struts ( Figure 4A ). The magnitude of clinical risk by OCT detected incomplete strut coverage is unknown and should likely be evaluated in combination with other healing variables. The LEADERS OCT sub-study found only 0.6% uncovered struts for BES after 9 months. 18 Recently the HATTRICK-OCT trial studying the Orsiro DES in non-diabetic patients with acute coronary syndrome found only 3.9% uncovered struts after 3 months 19 and a study of Orsiro DES in patients with STEMI, eligible for a two-step procedure, demonstrated coverage of 98.7% after 90 days. 20 For the Nobori DES, a similar level of coverage has recently been reported (in 17 patients, frequency of uncovered struts at 12-month: 1.55 ± 1.63%). 21 Direct inter-study comparison of coverage rates should be performed with caution as differences in implantation techniques, degree of lesion coverage, and fraction of patients with diabetes, could cause differences in the observed healing responses. Assuming an even distribution of neointimal tissue, an increased neointima area is related to the degree of strut coverage but excess hyperplasia is the main cause of in-stent restenosis 22 and the related angiographic measure of lumen loss is a well-established predictor of in-stent restenosis and TLR. 23, 24 In Nobori DES, the mean neointima area, the minimal lumen late loss and the mean lumen area late loss were increased, but NIT (tissue thickness on struts) did not differ and together with the increased fraction of patients with less than 90% coverage in the Nobori arm, this may indicate a more heterogeneous healing pattern after Nobori stenting with incomplete healed sections and sections with excess neointima formation.
Malapposition
Stent strut malapposition is a frequent finding in patients presenting with ST 25, 26 and several mechanisms have been proposed to increase the risk of acquired malapposition, such as stent recoil, vessel relaxation, positive remodelling, and localized evaginations of the vessel wall due to hypersensitive reactions. 17, 27 At baseline, we observed no difference in percentages of malapposed struts, and both stents demonstrated ability to resolve baseline malapposition with no significant difference in number of persistent or abolished clusters at 13-month follow-up. The small number of patients with acquired malapposition in clusters precludes firm conclusions about the acquired malapposition. Yet, our findings suggest a reaction towards the dissolving polymer in the Orsiro group and resolving thrombus/ vessel relaxation in the Nobori group.
Stent area and recoil
The stents were implanted with similar average balloon pressures in vessels with similar angiographic reference diameters. Still, a slightly smaller MSA in the Orsiro group was detected and might represent acute recoil. Late stent recoil was only found in lesions treated with the Nobori DES indicating that the thin strut Orsiro maintains sufficient radial strength over time and that the enhancement in ESL is not explained by late stent recoil.
Clinical endpoints
One-year clinical results in the main study, SORT OUT VII, 11 indicated non-inferiority of the Orsiro when compared with the Nobori DES. TLF occurred in 3.8% and 4.6% for the Orsiro and the Nobori DES, respectively, with a significantly lower rate of ST in the Orsiro than the Nobori group. A slightly lower rate of clinical events were found in our substudy-population which might be due to selection of a lower risk group for the OCT substudy or an effect of optimization of the PCI implantation result in some patients based on procedural OCT findings.
Clinical perspectives
The safety in use of first generation DES was compromised by incomplete healing and development of peri-stent evaginations and aneurysms. It has been reported that such healing patterns are almost absent with newer generation of DES, but the findings in our study challenges this perception. Careful evaluation of clinical outcome after discontinuation of DAPT is required and the findings may indicate that careful evaluation of healing patterns before introduction and widespread use of new stents is still warranted.
Study limitations
An inherent limitation of most OCT studies on stent performance is the follow-up selection of healthy survivors due to a low rate of patients with clinical events investigated by OCT. The study was one of the largest randomized OCT-studies on stent performance with matched baseline and follow-up analysis. Yet, the sample size remains minor and the most severely diseased patients omitted, which tends to increase the risk of type 1 and 2 errors. Coverage was verified if struts were clearly covered, but with the axial resolution of OCT at 10-15 mm, thin layers of tissue coverages (<10 mm) are not readily identified. 28 
Conclusion
Orsiro DES had a significantly larger increase in vessel lumen outside the stent (ESL) during follow-up than Nobori DES and it could not be ruled out if Orsiro DES exceeded the limit for non-inferiority in 13-month mean ESL. Nobori DES was associated with a healing pattern with more heterogeneous neointima distribution while stent strut coverage did not differ significantly between the two stents.
Supplementary data
Supplementary data are available at European Heart JournalCardiovascular Imaging online.
